Cytek Biosciences Inc (CTKB)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | -20,523 | -27,845 | -1,826 | 6,447 | 13,659 |
| Total assets | US$ in thousands | 499,500 | 494,457 | 519,476 | 463,700 | 219,979 |
| Operating ROA | -4.11% | -5.63% | -0.35% | 1.39% | 6.21% |
December 31, 2024 calculation
Operating ROA = Operating income ÷ Total assets
= $-20,523K ÷ $499,500K
= -4.11%
Operating return on assets (Operating ROA) is a key financial ratio that indicates a company's efficiency in generating profits from its operating assets. Analyzing Cytek Biosciences Inc's Operating ROA over the years reveals a concerning trend.
As of December 31, 2020, Cytek Biosciences Inc had an Operating ROA of 6.21%, indicating that the company was generating a positive return from its operating assets. However, there was a significant decline in performance as the Operating ROA dropped to 1.39% by December 31, 2021, and further deteriorated to -0.35% by December 31, 2022.
By December 31, 2023, Cytek Biosciences Inc experienced a substantial negative Operating ROA of -5.63%, implying that the company was operating at a loss concerning its assets during that period. This negative trend continued into December 31, 2024, with a further decline to -4.11%.
The consistent decline in Operating ROA over these years suggests that Cytek Biosciences Inc may be facing challenges in effectively utilizing its operating assets to generate profits. It is essential for the company to address these issues promptly to improve its operational efficiency and financial performance in the future.
Peer comparison
Dec 31, 2024